<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Medical Journal of the Islamic Republic Of Iran</title>
<title_fa>مجله پزشکی جمهوری اسلامی ایران</title_fa>
<short_title>Med J Islam Repub Iran</short_title>
<subject>Medical Sciences</subject>
<web_url>http://mjiri.iums.ac.ir</web_url>
<journal_hbi_system_id>2</journal_hbi_system_id>
<journal_hbi_system_user>journal2</journal_hbi_system_user>
<journal_id_issn>1016-1430</journal_id_issn>
<journal_id_issn_online>2251-6840</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.18869/mjiri</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1376</year>
	<month>5</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>1997</year>
	<month>8</month>
	<day>1</day>
</pubdate>
<volume>11</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>COMPARISON OF THE ACUTE BRONCHO DILATING EFFECTS OF INHALED IPRATROPIUM BROMIDE AND SALBUTAMOL IN PATIENTS WI TH CHRONIC OBSTRUCTIVE PULMONARY DISE ASE </title>
	<subject_fa>Pharmacology</subject_fa>
	<subject>Pharmacology</subject>
	<content_type_fa>Original Research</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>Forty-five patients with chronic obstructive pulmonary disease were studied
to compare the acute effects of ipratropium bromide (60 µg), salbutamol (300 µg)
and placebo (3 puffs) on the forced expiratory volume in 1 sec (FEV 1) and forced
vital capacity (PVC). Ipratropium bromide produced a significantly greater
improvement than salbutamol in both FEV1 and FVC at 15,60 and 180 minutes
after drug administration. It may therefore be concluded that in patients with
chronic obstructive pulmonary disease, ipratropium bromide has greater potency
and a longer duration of action than salbutamoL
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Ipratropium bromide, salbutamol, anticholinergic, chronic obstructive pulmonary disease.</keyword>
	<start_page>111</start_page>
	<end_page>114</end_page>
	<web_url>http://mjiri.iums.ac.ir/browse.php?a_code=A-10-1-373&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>S</first_name>
	<middle_name></middle_name>
	<last_name>MOHAMEDI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846005158</code>
	<orcid>20031947532846005158</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>From the Tehran University of Medical Sciences, Tehran, and the *Dept. of Pharmacology, Shaheed Beheshti University of Medical Sciences, Tehran, I.R. Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>F</first_name>
	<middle_name></middle_name>
	<last_name>ROSHANZAMIR</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846005159</code>
	<orcid>20031947532846005159</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>A</first_name>
	<middle_name></middle_name>
	<last_name>MAHDAVI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846005160</code>
	<orcid>20031947532846005160</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>MH</first_name>
	<middle_name></middle_name>
	<last_name>POURGHOLAMI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846005161</code>
	<orcid>20031947532846005161</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
